Copernicus Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Copernicus Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$96K	Buy	+10,000	New	+$102K	1.16%	13
2019 Q4	–	Sell	-335,000	Closed	-$2.69M	–	18
2019 Q3	$2.69M	Buy	335,000 +10,000	+3%	+$109K	2.5%	14
2019 Q2	$4.06M	Buy	+325,000	New	+$4.12M	3.61%	13
2018 Q4	–	Sell	-458,630	Closed	-$5.54M	–	18
2018 Q3	$5.54M	Buy	458,630 +85,832	+23%	+$1.2M	5.21%	8
2018 Q2	$5.82M	Sell	372,798 -2,572	-0.7%	-$38.9K	4.23%	11
2018 Q1	$5.65M	Sell	375,370 -82,247	-18%	-$1.25M	4.5%	11
2017 Q4	$6.58M	Buy	+457,617	New	+$6.29M	4.9%	7

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Copernicus Capital Management's FOLD Position: Q3 2021 in Review

Copernicus Capital Management opened a new position in Amicus Therapeutics (FOLD) in Q3 2021: 10,000 shares worth $96K. The stake represents 1.16% of the portfolio and ranks #13 among its holdings. This is a return to the name: Copernicus Capital Management previously reported a position in FOLD as recently as Q3 2019.

Copernicus Capital Management first reported a position in FOLD in Q4 2017 and has held it in 7 quarters since. The position peaked at $6.58M in Q4 2017. 236 funds tracked by Wall St. Rank hold FOLD as of Q3 2021.

Copernicus Capital Management held 10,000 shares of Amicus Therapeutics worth $96K as of Q3 2021.
Amicus Therapeutics was a new Copernicus Capital Management position in Q3 2021.
Amicus Therapeutics made up 1.16% of Copernicus Capital Management's portfolio in Q3 2021, its #13 holding.
Copernicus Capital Management first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 7 quarters since.
Copernicus Capital Management's Amicus Therapeutics position peaked at $6.58M in Q4 2017.
236 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2021.

Based on Copernicus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.